CSI Market
Sign In | Register

Castle Biosciences Inc (CSTL) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CSTL Annual Cash Flow →
Cash flow data covering Castle Biosciences Inc–Jun 30 2025 offers a view into how Jun 30 2026's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-16.58
Depreciation & amortization8.00
Amortization of Other Assets4.48
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.33
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation21.37
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Embedded Derivative Gain Loss On Embedded Derivative Net-
Other Non Cash Interest-
Increase Decrease In Operating Lease Right Of Use Assets0.37
Increase Decrease In Operating Lease Liability-0.17
Equity Securities Fv Ni Gain Loss-2.02
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-6.65
Increase (Decrease) in Accounts Payable0.89
Increase (Decrease) in Other Accrued Liabilities5.31
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets7.54
Other Working Capital0.79
Other Noncash Income (Expense)-0.77
Other net0.85
Payments for (Proceeds from) Other Operating Activities-32.47
Discontinued operations0.00
Net Cash flow from Operating Activities-6.93
Investing Activities
Capital Expenditures-21.11
Sale of Capital Items0.01
Proceeds from Sale and Maturity of Marketable Securities80.10
Payments to Acquire Available-for-sale Securities, Debt-109.62
Real Estate Investments0.00
Payments To Acquire Asset Acquisitions Net Of Cash Acquired-
Proceeds From Previous Asset Acquisition-
Asset Acquisition Adjustment To Purchase Price-
Proceeds From Sale Of Equity Securities Fv Ni2.68
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Finance Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net8.85
Discontinued operations0.00
Net Cash Flow from Investing Activities-41.77
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.52
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-7.39
Other net-1.05
Proceeds From Issuance Of Term Debt And Preferred Stock Warrants Net Of Issuance Costs-
Proceeds From Issuance Of Convertible Debt And Common Stock Warrants Net Of Issuance Costs-
Finance Lease Principal Payments-0.02
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-5.92
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-28.02
Total Cash Flow-54.61
4 historic quarters locked

Sign in to unlock the full Castle Biosciences Inc cash flow history.

Sign In Create Free Account

About Castle Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-051052

Figures are derived from filed reports and may be restated. Historical data is subject to revision.